AOD-9604 INJECTOR PEN 3ML 6MG

AOD-9604 Injector Pen: The hGH Fragment Peptide for Targeted Fat-Metabolism, Endurance Research and Body Composition Support (Now Available in UAE)

In the evolving world of metabolic peptide science, AOD-9604 (Tyr-hGH177-191) stands out as a synthetic fragment derived from the C-terminal “lipolytic domain” of human growth hormone (hGH). Engineered with an added N-terminal tyrosine to enhance stability, AOD-9604 was originally developed to help researchers isolate the fat-mobilizing properties of hGH while avoiding the classic growth-hormone pathway effects that raise concerns in long-term use (e.g., IGF-1 elevation and glucose intolerance). By focusing on adipose-tissue lipid handling and downstream metabolic signaling, AOD-9604 became an investigational candidate for obesity and related metabolic research—drawing attention for its appetite-neutral, fat-metabolism–oriented concept.

Our AOD-9604 injector pen is designed for convenient handling and measured administration in controlled research settings. While AOD-9604 underwent multiple clinical studies primarily using oral and intravenous dosing formats, it is not FDA-approved for obesity or “weight loss,” and U.S. regulatory review has highlighted that the available human efficacy evidence is limited and mixed (including the absence of a full peer-reviewed publication for the key 12-week multicenter study and negative outcomes in the larger 24-week Phase 2B trial that led to discontinuation of development for obesity). Below, we explore five key research-backed areas of interest for AOD-9604, with direct links to scientific and regulatory sources including PubMed, peer-reviewed journals, and FDA documentation. (U.S. Food and Drug Administration)

1. Stimulation of Lipolysis and Reduced Fat Accumulation in Preclinical Obesity Models

AOD-9604’s core scientific appeal is its ability shown in multiple preclinical models to increase lipolytic activity (fat breakdown) in adipose tissue and reduce fat accumulation over time. In obese Zucker rats, daily oral administration of AOD-9604 was associated with markedly reduced body weight gain and increased lipolytic activity in adipose tissue compared with controls, supporting the idea that the peptide can shift fat metabolism toward mobilization rather than storage in an obesity model. (PubMed)

These findings align with related mechanistic work on the broader lipolytic domain of hGH (often discussed alongside AOD-9604 research) showing increased lipolysis and reduced lipogenesis signals in adipose tissue, reinforcing why AOD-9604 has remained of interest as a research tool for studying fat-mobilization pathways. (PubMed)

2. Increased Fat Oxidation and Energy Expenditure Signals in Animal Studies

Beyond mobilizing stored fat, AOD-9604 has been studied for its association with increased fat oxidation an important downstream step where liberated fatty acids are actually burned for energy. In obese mouse studies, chronic treatment with AOD-9604 was associated with reduced body weight gain and increased in vivo fat oxidation, with plasma glycerol increases used as a supportive marker of lipolysis. Notably, these studies framed AOD-9604 as capturing some metabolic effects of hGH while potentially avoiding some classic growth-hormone liabilities. (PubMed)

In parallel mechanistic experiments, AOD-9604 was also reported to increase energy expenditure and fat oxidation even in β3-adrenergic receptor knock-out mice under certain conditions helpful for researchers trying to map where AOD-9604 sits in the network of adrenergic and metabolic regulation. (PubMed)

3. Mechanistic Support for Adipose “Lipolytic Sensitization” via β3-Adrenergic Pathways

A differentiator in the AOD-9604 literature is its repeated association with β3-adrenergic receptor (β3-AR) signaling in adipose tissue one of the major pathways involved in fat-cell lipolysis. In a well-cited Endocrinology study, chronic treatment with AOD-9604 in obese mice was linked to increased β3-AR RNA expression and increased lipolytic sensitivity, and the authors used β3-AR knock-out mice to test whether this receptor was necessary for certain observed effects. (PubMed)

For research programs focused on obesity biology, this matters because β-adrenergic responsiveness is often impaired in obesity; a compound that appears to “restore” or enhance lipolytic responsiveness in preclinical settings can be a valuable probe for studying adipose signaling, energy balance, and fat-mobilization dynamics. (PubMed)

4. Favorable Safety and Tolerability Signals in Human Trials, Including IGF-1 and Glucose Metrics

AOD-9604’s strongest human evidence base is in safety/tolerability rather than efficacy. A peer-reviewed safety summary in the Journal of Endocrinology and Metabolism reported that across multiple randomized, double-blind, placebo-controlled trials (with a total participation on the order of hundreds of subjects across programs), AOD-9604 had no meaningful effect on serum IGF-1 (supporting the hypothesis that it does not activate the classic hGH/IGF-1 axis), showed no negative effect on carbohydrate metabolism measures (including oral glucose tolerance testing), and did not produce detectable anti-AOD-9604 antibodies in tested subsets.

This “non-IGF” profile is central to how AOD-9604 is positioned scientifically: it was designed as a fragment that is missing key elements needed for full growth hormone receptor activation, with the intent of reducing growth-promoting and diabetogenic risks associated with intact hGH exposure.

5. Early Human Efficacy Signals Were Reported, But Overall Evidence Is Mixed and Obesity Development Was Discontinued

AOD-9604 has been evaluated in humans for obesity-related endpoints, but the public evidence supporting meaningful clinical weight loss is inconsistent and incomplete. In an FDA Pharmacy Compounding Advisory Committee briefing document (Dec 4, 2024), FDA summarizes multiple small early trials (including IV and oral dosing studies) where markers such as non-esterified fatty acids (NEFA) increased as expected for fat-metabolism changes, but weight loss was not statistically different from placebo in those early studies. The same FDA document discusses a 12-week, multicenter, randomized, placebo-controlled study (reported as a meeting abstract) that claimed greater weight loss rates and waist circumference reductions versus placebo; however, FDA explicitly notes that interpretation is limited due to minimal data in the abstract and the lack of a full publication detailing methods and results. (U.S. Food and Drug Administration)

Most importantly for realistic expectation-setting, FDA also summarizes that the larger Phase 2B “OPTIONS Study” in obesity did not meet the primary endpoint for statistically significant weight loss versus placebo, and FDA documents that the sponsor publicly announced termination of development for obesity based on insufficient efficacy. (U.S. Food and Drug Administration)

Why Choose Our AOD-9604 Injector Pen?

Our AOD-9604 offering is designed for researchers who want a streamlined, precise format for peptide handling in controlled settings. If you’re studying fat metabolism, adipose signaling, or metabolic pathway modulation, AOD-9604 represents a historically well-characterized hGH-fragment tool with a relatively robust human safety discussion paired with clear, transparent limitations on demonstrated clinical weight-loss efficacy. Always consult qualified professionals and follow all applicable laws, protocols, and institutional policies when handling research compounds.

Note: These statements summarize scientific literature and regulatory reviews and are not intended to diagnose, treat, cure, or prevent any disease.

Scientific Studies:

1.Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (Hormone Research, 2000)
2.The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice (Endocrinology, 2001)
3.Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment (Int J Obes, 2001)
4.Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (J Endocrinol Metab, 2013)
5.Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism (Am J Physiol Endocrinol Metab, 2000)

Disclaimer: The summaries above describe findings from published scientific studies and are provided for educational and research‑discussion purposes only. They are not intended to diagnose, treat, cure, or prevent any disease, and they are not a substitute for medical advice. Therefore this product is not intended to be for human consumption!